Picture Berlin Partner Hotspot for Startups 650x80px
Product › Details

Metzler MicroCap Day

Products Next higher product group conference, investment / investor / financing / VC

Medigene AG. (3/28/17). "Press Release: Medigene Announces Participation at Six National and International Conferences". Planegg.

Medigene AG (FWB: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming scientific and investor conferences:

* Metzler MicroCap Day
Date: March 29 - 30, 2017
Location: Frankfurt/Main, Germany

* American Association for Cancer Research - AACR Annual Meeting
Date: April 1 - 5, 2017
Location: Washington DC, USA
Dr. Manon Weis, scientist, gives an oral presentation on April 4th at 03.05 PM
on the topic: "Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile". An abstract is available under: ( !/4292/presentation/5970)

Furthermore, our cooperation partner from the Oslo University Hospital will present a poster on April 4th during 08.00 AM to 12.00 PM on the topic: "WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival". An abstract is available under: ( !/4292/presentation/5996)

* 16th Annual Needham Healthcare Conference
Date: April 4 - 5, 2017
Location: New York, USA
Medigenes CFO, Dr. Thomas Taapken, will hold a company presentation on April 4th at 05.00 PM.

* 24th BioCentury Future Leaders in the Biotech Industry
Date: April 7, 2017
Location: New York, USA
Medigenes CFO, Dr. Thomas Taapken, will hold a company presentation at 10.30 AM.

* Molecular Diagnostics Europe
Date: April 10 - 13, 2017
Location: Lisbon, Portugal

* European Neoantigen Summit 2017
Date: April 24 -26, 2017
Location: Amsterdam, Netherlands
Prof. Dolores Schendel, Medigenes CEO / CSO, gives a presentation on April 26th at 01.45 PM on the topic: "Rapid High-Throughput Technologies Allow Functional Identification of Neoantigens for Vaccines and TCR-Based Immunotherapies".

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in clinical and pre-clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Record changed: 2017-04-03


Picture EBD Group Global Partnering Four Events One Price 650x80
» Show all Events!

Metzler MicroCap Day

Past & forthcoming events

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our free web portals (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px

» top